期刊
ACR OPEN RHEUMATOLOGY
卷 4, 期 1, 页码 57-64出版社
WILEY
DOI: 10.1002/acr2.11334
关键词
-
类别
资金
- Amgen
- Pfizer Canada
- AbbVie Corporation
- Hoffmann-LaRoche
- Medexus Inc.
- Merck Canada
- Sandoz Canada
- Sandoz Canada, Biopharmaceuticals
- Gilead Sciences Canada
- Fresenius Kabi Canada Ltd.
- Janssen Biotech
- UCB Canada
- Bristol-Myers Squibb Canada
- Sanofi Genzyme
- Eli Lilly Canada
In a cohort of early rheumatoid arthritis patients, oral glucocorticoid use was associated with more active disease and increased likelihood of progressing to biologic therapy over a 24-month period. Despite guidelines to limit corticosteroid use, a significant proportion of patients continued using them long term.
Objective To describe patterns of glucocorticoid use in a large real-world cohort with early rheumatoid arthritis (RA) and assess the impact on disease activity and treatment. Methods Data are from adults with new RA (<= 1 year) recruited to the Canadian Early Arthritis Cohort (CATCH) and are stratified on the basis of whether a person was prescribed oral glucocorticoids within 3 months of study entry. Disease activity was compared over 24 months. Mixed-effects logistic regression was used for adjusted odds ratios (aORs) of escalation to biologics separately for 12 and 24 months, with random effects terms to account for prescribing patterns clustering by study site. Results Among 1891 persons, 30% received oral steroids. Users were older, were less often employed, and had shorter disease duration and higher disease activity. Disease activity improved over time, with early glucocorticoid users starting at higher levels of disease activity. Participants with early oral glucocorticoids were more likely to be on a biologic at 12 months (aOR = 2.4; 95% confidence interval [CI], 1.5-3.7) and 24 months (aOR = 1.9; 95% CI, 1.3-3.0). Despite Canadian clinical practice guidelines to limit corticosteroid use to short-term or 'bridge' therapy, 30% of patients who used oral glucocorticoids still used them 2 years later. Conclusion Early steroids were prescribed sparingly in CATCH and were often indicative of more active baseline disease as well as the need for progression to biologics.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据